> top > projects > sentences > docs > PubMed:24088574 > annotations
sentences Home  

PubMed:24088574 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-132 Sentence denotes The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.
T1 0-132 Sentence denotes The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.
TextSentencer_T2 133-144 Sentence denotes BACKGROUND:
T2 133-144 Sentence denotes BACKGROUND:
TextSentencer_T3 145-216 Sentence denotes Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer.
T3 145-216 Sentence denotes Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer.
TextSentencer_T4 217-351 Sentence denotes While current treatment regimens achieve almost 80% overall survival, long-term side effects of chemotherapeutic agents can be severe.
T4 217-351 Sentence denotes While current treatment regimens achieve almost 80% overall survival, long-term side effects of chemotherapeutic agents can be severe.
TextSentencer_T5 352-502 Sentence denotes The functional BCL2-938C > A promoter polymorphism is known to influence the balance between survival and apoptosis of malignant hematolymphoid cells.
T5 352-502 Sentence denotes The functional BCL2-938C > A promoter polymorphism is known to influence the balance between survival and apoptosis of malignant hematolymphoid cells.
TextSentencer_T6 503-597 Sentence denotes We investigated its usefulness as a marker for treatment stratification for children with ALL.
T6 503-597 Sentence denotes We investigated its usefulness as a marker for treatment stratification for children with ALL.
TextSentencer_T7 598-606 Sentence denotes METHODS:
T7 598-606 Sentence denotes METHODS:
TextSentencer_T8 607-747 Sentence denotes We analyzed DNA from 182 children suffering from ALL in this study to determine genotypes of the -938 C > A polymorphism by "slow-down" PCR.
T8 607-747 Sentence denotes We analyzed DNA from 182 children suffering from ALL in this study to determine genotypes of the -938 C > A polymorphism by "slow-down" PCR.
TextSentencer_T9 748-873 Sentence denotes RESULTS: ALL patients with the BCL2-938CC genotype had an approximately 3-fold higher risk of belonging to a high-risk group.
T9 748-873 Sentence denotes RESULTS: ALL patients with the BCL2-938CC genotype had an approximately 3-fold higher risk of belonging to a high-risk group.
TextSentencer_T10 874-1093 Sentence denotes Within the high-risk group, 50% of BCL2-938CC patients were classified as high-risk due to poor prednisone response whereas only 33% of patients with AC and AA genotypes were classified as high-risk for the same reason.
T10 874-1093 Sentence denotes Within the high-risk group, 50% of BCL2-938CC patients were classified as high-risk due to poor prednisone response whereas only 33% of patients with AC and AA genotypes were classified as high-risk for the same reason.
TextSentencer_T11 1094-1106 Sentence denotes CONCLUSIONS:
T11 1094-1106 Sentence denotes CONCLUSIONS:
TextSentencer_T12 1107-1349 Sentence denotes Our results suggest that BCL2-938C > A genotyping may be beneficial for therapy response prediction in ALL patients, and warrant examination in a larger cohort to validate its usefulness for treatment stratification of pediatric ALL patients.
T12 1107-1349 Sentence denotes Our results suggest that BCL2-938C > A genotyping may be beneficial for therapy response prediction in ALL patients, and warrant examination in a larger cohort to validate its usefulness for treatment stratification of pediatric ALL patients.